Safety Study of Adoptive Transfer of Autologous IKDC-like Cells

Inclusion Criteria: * Histologically confirmed metastatic/recurrent non-hematological cancer, stage IV at study entry. * Age: 21-75 years. * ECOG performance status 0-1. * Patients must have at least one measurable lesion. * Patients' disease must have failed at least one-line of standard chemotherapy/targeted therapy or other treatment in the metastatic setting. * Patients' estimated life expectancy is more than 3 months. * Patients who refuse chemotherapy, or who are physiologically unsuitable for chemotherapy or any other standard therapy per investigator's discretion will be considered eligible for this trial. * Patients must have adequate bone marrow function, defined as WBC ≥ 3500/mm3, neutrophil ≥ 1500/mm3, lymphocyte ≥ 1,000/mm3, and platelet ≥ 100,000/mm3. * Patients must have adequate liver and renal function, defined as serum alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 5 times normal, bilirubin ≤ 1.5 times normal range, and creatinine ≤ 1.5 times upper normal limit. * All patients should have documentation of negative result of penicillin test. * Women or men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method. * All patients must be informed of the investigational nature of this study and must sign and give written informed consent. Exclusion Criteria: * Subjects with metastatic cancer in disease progression (expected survival time \< 3 months). * Subjects who have had chemotherapy less than 4 weeks before the start of trial. * Subjects who received IFN-γ or GM-CSF less than 4 weeks before the start of trial. * Subjects who are HIV, HBV, or HCV positive. * Patients who have central nervous system metastasis except for those whose CNS disease have been treated with radiotherapy (Disease-free \> 6 months) and/or surgery and have been stable for at least two weeks. * Patients who have active acute or chronic infection (at the discretion of the investigator). * Pregnant or breast-nursing women. * Patients who have active cardiac disease requiring therapy for failure, angina, arrhythmia, or infarction within the preceding 6 months (exception: any patient whose cardiac failure is compensated on medications). * Subjects who have received corticosteroids or other immunosuppressive agents less than 4 weeks before starting trial. * Subjects who have asthma and/or are on treatment for asthma. * Subjects with history of autoimmune disease, such as lupus, multiple sclerosis, Ankylosing Spondylitis, Systemic Sclerosis. * Subjects with a history of other systemic disease.. * History of neoplastic disease within the last 5 years except for carcinoma in situ of the cervix, superficial bladder cancer or basal/squamous cell carcinoma of the skin. * Subjects who present with open wounds.